Potential Revance Therapeutics, Inc. (NASDAQ:RVNC) shareholders may wish to note that the CEO & Director, Mark Foley, recently bought US$209k worth of stock, paying US$6.98 for each share. Although the purchase only increased their holding by 2.9%, it is still a solid purchase in our view.

Check out our latest analysis for Revance Therapeutics

Revance Therapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by CEO & Director Mark Foley was not the only time they traded Revance Therapeutics shares this year. Earlier in the year, they sold shares at a price ofUS$34.55 per share in a -US$2.4m transaction. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$6.01). So it may not tell us anything about how insiders feel about the current share price.

Over the last year we saw more insider selling of Revance Therapeutics shares, than buying. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Revance Therapeutics insiders own about US$11m worth of shares. That equates to 1.8% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Revance Therapeutics Insiders?

It's certainly positive to see the recent insider purchase. But we can't say the same for the transactions over the last 12 months. We don't take much heart from transactions by Revance Therapeutics insiders over the last year. But they own a reasonable amount of the company, and there was some buying recently. So they seem pretty well aligned, overall. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 4 warning signs we've spotted with Revance Therapeutics (including 1 which is concerning).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.